The Council of Scientific and Industrial Research (CSIR) and Aurobindo Pharma Limited on Tuesday introduced a collaboration to develop vaccines for COVID-19.
As per the discharge issued by the Centre for Cellular & Molecular Biology (CCMB), underneath the signed settlement between CSIR- CCMB and Aurobindo Pharma, Aurobindo will accomplice with CSIR for the event of a number of novel COVID-19 vaccines.
“Three CSIR labs namely CCMB Hyderabad, Institute of Medical Technology (IMTECH), Chandigarh and Indian Institute of Chemical Biology (IICB), Kolkata are developing vaccine candidates using different technology platforms. Aurobindo will undertake clinical development and commercialization of the vaccines,” it mentioned.
Commenting on this partnership, Dr Shekhar C Mande, Director General, CSIR, mentioned that “Joining of hands of premier CSIR labs with industry for the development of vaccines will amplify India’s efforts in indigenous vaccine development and also help in preparedness for future pandemics”.
Dr. Rakesh Mishra, Director, CSIR-CCMB, whereas speaking concerning the growth methods for the vaccines mentioned, “Our labs are working on novel proteins for vaccine development that has the potential to address the need for a second-generation vaccine. We are happy to partner with Aurobindo who have proven manufacturing and commercialization capabilities.”
Aurobindo Pharma Limited additionally expresses satisfaction over the collaboration with CSIR for creating vaccines to fight the COVID-19 pandemic and mentioned that’s already organising a large-scale facility in Hyderabad for manufacturing the vaccine.
“We are proud to join hands with CSIR for developing vaccines to combat the COVID-19 pandemic. This collaboration further strengthens our COVID-19 vaccine development efforts. We are already setting up a large-scale facility in Hyderabad for manufacturing COVID-19 vaccine and other viral vaccines,” mentioned N. Govindarajan, Managing Director, Aurobindo Pharma Limited.
The launch mentioned that other than this collaboration, Aurobindo is already creating a vaccine for COVID-19 (SARS COV-2) by way of its wholly-owned US subsidiary Auro Vaccines.
“The SARS COV-2 vaccine candidate is based on the company’s proprietary replication-competent, attenuated, recombinant vesicular stomatitis (VSV, VesiculoVax(tm)) vaccine delivery platform,” it added.
(This story has not been edited by NDTV employees and is auto-generated from a syndicated feed.)